N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses

A method of treating a disorder selected from the group consisting of myelodysplastic syndrome, Parkinson's disease, complex regional pain syndrome, aphthous ulcers, cachexia, graft versus host disease, inflammation of the lungs, depression, atopic dermatitis, diabetic retinopathy, systemic lupus, and multiple sclerosis, in a mammal in need thereof comprising administering to said mammal an effective amount of a compound of formula I:

• wherein:
• Y is —C(O)—, —CH2—, or —CH2C(O)—;
• R1 and R2 are each independently C1-8-alkyl, CF2H, CF3, CH2CHF2, cycloalkyl, or (C1-8-alkyl)cycloalkyl;
• Z1 is H, C1-6-alkyl, NH2, NR3R4 or OR5;
• Z2 is H or C(O)R5;
• X1, X2, X3 and X4 are each independently H, halogen, NO2, OR3, CF3, C1-6-alkyl, (C0-4-alkyl)-(C3-6-cycloalkyl), (C0-4-alkyl)-N—(R8R9), (C0-4-alkyl)-NHC(O)—(R8), (C0-4-alkyl)-NHC(O)CH(R8)(R9), (C0-4-alkyl)-NHC(O)N(R8R9), (C0-4-alkyl)-NHC(O)O(R8), (C0-4-alkyl)-O—R8, (C0-4-alkyl)-imidazolyl, (C0-4-alkyl)-pyrrolyl, (C0-4-alkyl)-oxadiazolyl, (C0-4-alkyl)-triazolyl or (C0-4-alkyl)-heterocycle;
• R3, R4, and R5 are each independently H, C1-6-alkyl, O—C1-6-alkyl, phenyl, benzyl, or aryl;
• R6 and R7 are independently H or C1-6-alkyl;
• R8 and R9 are each independently H, C1-9-alkyl, C3-6-cycloalkyl, (C1-6-alkyl)-(C3-6-cycloalkyl), (C0-6-alkyl)-N(R4R5), (C1-6-alkyl)-OR5, phenyl, benzyl, aryl, piperidinyl, piperazinyl, pyrrolidinyl, morpholino, or C3-7-heterocycloalkyl;
• or a pharmaceutically acceptable salt thereof
• or an enantiomer or diastereomer thereof.